PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer

Table 4 Comparison of TMB status in ADC and SQCC study groups

Characteristic	ADC				P value	SQCC				P value
Characteristic	High (n, %)		Low/Moderate (n, %)		P value	High (n, %)		Low/Moderate (n, %)		P value
Age (years)					0.805					1
<58 (< 60) #	9	14%	55	86%		7	29%	17	71%
≥58 (≥60)	9	13%	63	87%		7	26%	20	74%
Sex					0.068					0.704
Male	15	17%	71	83%		12	30%	28	70%
Female	3	6%	47	94%		2	18%	9	82%
Smoking status					1					0.512
Never smoker	15	14%	94	86%		11	31%	25	69%
Smoker	3	11%	24	89%		3	20%	12	80%
Pathologic stage					0.796					0.529
IIIB	8	15%	46	85%		7	33%	14	67%
IV	10	12%	72	88%		7	23%	23	77%
Mutation status					0.049					\
EGFR mutant	4	7%	54	93%		0	0%	2	100%
KRAS mutant	5	29%	12	71%		2	100%	0	0%
Other	9	15%	52	85%		12	26%	35	74%
PD-L1 in TC
Strong+	7	26%	20	74%	0.051	8	57%	6	43%	0.01
Moderate/strong+	8	22%	28	78%	0.084	10	48%	11	52%	0.01
Any+	9	18%	41	82%	0.293	11	39%	17	61%	0.058
Negative	9	10%	77	90%		3	13%	20	87%
PD-L1 in IC
Strong+	6	22%	21	78%	0.199	1	8%	11	92%	0.141
Moderate/strong+	6	18%	28	82%	0.389	1	7%	13	93%	0.076
Any+	8	17%	40	83%	0.431	7	24%	22	76%	0.752
Negative	10	11%	78	89%		7	32%	15	68%

ISSN: 1756-9966